[A clinical trial of creatine monohydrate in muscular dystrophy patients].
To investigate the effects of creatine monohydrate on muscle performance and cognitive functions in muscular dystrophy patients, we made an open trial. Twenty-nine individuals, including 14 myotonic dystrophy (DM), seven facioscapurohumeral muscular dystrophy (FSHD), two limb-girdle muscular dystrophy and six healthy volunteers, were enrolled in this study and 27 participants completed it. All participants took creatine 20g/day for an initial week and 5g/day for successive eight weeks. Somatotonic measurements, global subjective assessment, muscle performance, cardiopulmonary function, cognitive function, laboratory studies and magnetic resonance spectroscopy (MRS) were evaluated at both pre and post examination. Subjective improvements were reported from twelve individuals. Contrary adverse effects were also complained from ten individuals, although all these problems were not serious. Quantitative muscle power was slightly but significantly increased in the patients and the number of the patients who failed to complete cycle ergometer test was decreased. Phosphocreatine concentrations of left calf muscle were not different between pre and post trial examination. No obvious changes were detected in cardiopulmonary assessment, cognitive function and laboratory date. Creatine has certain expectance for muscular dystrophy patients in motor performance. The effect may be achieved not only by increase of energy buffer, because clinical improvements were observed in our study nevertheless no increase was detected in phosphocreatine concentration. The usage of creatine should be managed under medical monitoring since ideal protocol has not yet been established and adverse effects can not be ignored.
Matsumura
Tsuyoshi
T
Department of Neurology, National Hospital Organization Toneyama National Hospital.
Yokoe
Masaru
M
Nakamori
Masayuki
M
Hattori
Noriaki
N
Saito
Toshio
T
Nozaki
Sonoko
S
Fujimura
Harutoshi
H
Shinno
Susumu
S
D000203:Activities of Daily Living; D000293:Adolescent; D000328:Adult; D003401:Creatine / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D009682:Magnetic Resonance Spectroscopy; D008297:Male; D008875:Middle Aged; D009136:Muscular Dystrophies / Q000188:drug therapy* / Q000503:physiopathology; D020391:Muscular Dystrophy, Facioscapulohumeral / Q000188:drug therapy
D003401:Creatine